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Abstract
Purpose of Review In this review, we discuss the key molecular and clinical developments in VHL disease that have the potential
to impact on the natural history of the disease and improve patient outcomes.
Recent Findings Identifiable mutations in VHL underlie most cases of VHL and define clear genotype-phenotype correlations.
Detailed clinical and molecular characterisation has allowed the implementation of lifelong screening programmes that have
improved clinical outcomes. Functional characterisation of the VHL protein complex has revealed its role in oxygen sensing and
the mechanisms of tumourigenesis that are now being exploited to develop novel therapies for VHL and renal cancer.
Summary The molecular and cellular landscape of VHL-associated tumours is revealing new opportunities to modify the natural
history of the disease and develop therapies. Drugs are now entering clinical trials and combined with improved clinical and
molecular diagnosis, and lifelong surveillance programmes, further progress towards reducing the morbidity and mortality
associated with VHL disease is anticipated.
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Introduction
von Hippel-Lindau (VHL) disease is an autosomal dominant
multisystem cancer predisposition disorder caused by
germline mutations in the VHL tumour suppressor gene [1,
2]. Up to 20% of cases are due to de novo pathogenic variants
and therefore have no family history [3]. VHL disease dem-
onstrates age-dependent and incomplete penetrance and vari-
able expression [4–6]. The most common tumours associated
with VHL disease are retinal and central nervous system
haemangioblastomas (in the cerebellum, brain stem or spinal
cord ) , c l ea r ce l l rena l ce l l ca rc inoma (cRCC) ,
phaeochromoctyma/paraganglioma (PPGL), non-secretory
pancreatic neuroendocrine tumours and endolymphatic sac
tumours [4, 6] (see Table 1). Visceral (renal, pancreatic and
epididymal) cysts occur frequently and may suggest the diag-
nosis when they are detected in combination with a VHL-
related tumour [6].
Comprehensive reviews of the historical, clinical and mo-
lecular aspects of VHL disease and the VHL tumour suppres-
sor gene (TSG) have been published in the past 5 years [1, 2].
In this brief review, we discuss some of the key molecular and
clinical aspects of VHL disease and highlight some of the
recent relevant literature focussing on developments that have
the potential to impact on the natural history of the disease and
improve patient outcomes.
Genetics of VHL Disease
VHL disease is caused by monoallelic pathogenic variants in
the VHL tumour suppressor gene which maps to chromosome
3p25 [1, 7]. VHL disease causing VHL variants are heteroge-
neous and include single or multi-exon deletions (30–40% of
cases), truncating mutations (~ 30% of case) and missense
variants (~ 30%) [5, 8]. The VHL gene encodes two proteins,
a full length 213 amino acid protein and a shorter one that is
translated from a second initiation site at codon 54 (pVHL30
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and pVHL19 respectively). Loss of function variants that im-
pact on both proteins are pathogenic and no phenotype has
been associated with variants that only alters the longer form
[8] (Fig. 1). Genotype-phenotype correlations are a well-
recognised feature of VHL disease (see Table 2). VHL type
1 disease is associated with the development of retinal and
CNS haemangioblastomas and cRCC but rarely PPGL and
pathogenic variants in this group of patients are usually exon
deletions, truncating variants or missense variants that are pre-
dicted to destabilise pVHL [1, 2]. VHL type 2 disease is as-
sociated with frequent PPGL and the pathogenic variants de-
tected are most often missense substitutions at pVHL surface
residues. Type 2 VHL disease is further subdivided into type
2A (PPGL, haemangioblastomas but not RCC), type 2B
(PPGL, haemangioblastomas and RCC) and type 2C (PPGL
only) and specific missense substitutions can be found in each
subtype [1, 2]. A further genotype-phenotype correlation is the
association of congenital polycythaemia with specific biallelic
missense variants (e.g. p.Arg200Trp) [9].
Clinical diagnostic criteria for VHL disease (e.g. a typical
VHL type tumour in an individual with a family history of
VHL disease or in sporadic cases two haemangioblastomas or
a haemangioblastoma and a visceral tumour) can lead to under
or late diagnosis of VHL disease particularly in patients with-
out a family history but the availability of routine molecular
genetic testing for more than two decades has therefore en-
abled accurate and earlier diagnosis [6]. A molecular diagno-
sis can be made 95% or more of individuals with a clinical
Fig. 1 Distribution of germline variants across the VHL coding sequence
in patients diagnosed with von Hippel-Lindau disease. Data extracted
from the missense and in frame deletion (“missense/IFD”) and
nonsense/frameshift variants (“truncating”). Data extracted from http://
vhldb.bio.unipd.it/mutations [8]
Table 1 Major neoplasms in
VHL disease (adapted from
Nielsen et al. [2])




Retinal haemangioblastoma 25–60% 25 1–68
Cerebellar haemangioblastoma 44–72% 33 9–78
Renal cell carcinoma 25–50% 39 16–70
Spinal haemangioblastoma 15–50% 33 11–66
Phaeochromocytoma 10–25% 27 5–58
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diagnosis of VHL disease. To date, there is no evidence for
locus heterogeneity and, with the increasing use of next gen-
eration sequencing techniques, the suspicion that a proportion
of cases without a molecular diagnosis are mosaic for a path-
ogenic variant in peripheral blood has been confirmed.
Interestingly, though it might be predicted that mosaic cases
might more mildly affected, low levels of mosaicism have
been reported in individuals with a classical VHL disease
phenotype [10, 11]. Less commonly, promoter region variants
have been reported to be pathogenic [12]. Recently, intronic
variants or synonymous variants in exon 2 (of three VHL
exons) have been reported to result in dysregulated splicing
and cause VHL disease, familial phaeochromocytoma and,
when homozygous/compound heterozygous state, with
erythrocytosis [13•, 14]. These novel findings suggest that
mutation negative individuals in whom VHL disease is
strongly suspected should be now re-evaluated for further ge-
netic testing. Somatic mutation testing may eventually help
define disease in the very small number of cases with no
evidence of mosaicism in blood.
Mechanisms of Tumourigenesis in VHL
Disease and Sporadic VHL-Related Tumours
Prior to the identification of the VHL TSG, statistical anal-
ysis had demonstrated that the ages at onset of cerebellar
haemangioblastomas and RCC in VHL disease and sporad-
ic cases were consistent with a one-hit and two-hit model
of tumourigenesis (as in retinoblastoma) [15]. Subsequent
molecular studies confirmed this with somatic inactivation
occurring in most clear cell RCC and in tumours from
patients with VHL disease, the somatic inactivation
of VHL i s presen t as second hi t [16–19] . CNS
haemangioblastomas comprise a mixture of stromal cells,
pericytes, endothelial cells and lymphocytes. Though the
neoplastic component is the stromal cells, these only ac-
count for ~ 20% of the tumour [20]. Deep sequencing has
demonstrated that, as in sporadic cRCC, somatic VHL in-
activation can be detected within the stromal cells in most
sporadic haemangioblastomas [21].
Phenotypic variability is a prominent feature of VHL dis-
ease and, in addition to allelic heterogeneity, genetic modifier
and stochastic events have been implicated [5, 22]. Analysis
of somatic variants frommultiple cRCC from individuals with
VHL disease has confirmed that they are clonally independent
but also that within-patient patterns are identifiable, implicat-
ing a role for genetic background and environmental effects in
influencing the acquisition of somatic mutations [23]. Whilst
biallelic VHL inactivation is apparently necessary for
tumourigenesis, in most sporadic clear cell RCC (cRCC, the
most common type of RCC), current models of
tumourigenesis specify that VHL inactivation alone is not
sufficient to for tumourigenesis. In addition to somatic VHL
mutations, most cRCC demonstrates loss of the short arm of
chromosome 3 that extends far centromeric (e.g. to 3p12 or
3p14) to VHL at 3p25 [24–27]. These large 3p deletions will
result in loss of one allele of other 3p TSGs such as the epi-
genetic regulators BAP1, PBRM1 and SETD2 and somatic
mutations in these genes can be detected in many sporadic
cRCC [28–31]. A number of recent studies have looked at
the relationship between VHL and BAP1 or PBRM1 inactiva-
tion. In a mouse model, a combination of Vhl−/− and Bap1+−
deficiency in nephron progenitor cells resulted in multiple
renal cysts and tumours (similar to kidneys in VHL disease)
whereas Vhl−/−mice did not develop cRCC [32]. Similarly, in
cellular and mouse models, loss of PBRM1/Pbrm1 in addition
to VHL/Vhl was oncogenic [33–35].
Table 2 Summary of reported
genotype-phenotype relationships
in von Hippel-Lindau disease.
Though these relationships are




sometimes in patients with VHL
variants that would predict type 1
disease
VHL subtype VHL mutation type Typical phenotype
Type 1 Exonic deletions, protein truncating variants
missense causing protein instability
Retinal haemangioblastomas
CNS haemangioblastomas
Renal cell carcinoma (clear cell)









Type 2B Missense; e.g. p.Arg167Trp, p.Arg167Gln Retinal haemangioblastomas
CNS haemangioblastomas
Renal cell carcinoma (clear cell)
Phaeochromocytoma
Type 2C Missense; e.g. p.Val84Leu Phaeochromocytoma
CNS, central nervous system
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In a seminal study, Mitchell et al. [36••] reported that the
most frequent cause of chromosome 3p loss in cRCC is a
chromothrypsis-associated rearrangement between 3p and 5q
that resulted in loss of 3p and gain of 5q. It was estimated that
the t(3;5) initiating event occurred early in life (childhood/
adolescence) in the majority of cases, preceding other driver
mutations and 30–50 years before the diagnosis of RCC
[36••]. In a reanalysis of genome data from VHL disease
RCC, there was a similar frequency of t(3;5) and age-related
rate of accumulation of somatic mutations as in sporadic
cRCC [23, 36••]. Though it was predicted that both VHL-
related RCC and sporadic cRCC would be initiated by
biallelic VHL inactivation [15], the first event in VHL RCC
is a germline VHLmutation whilst in sporadic cRCC, the first
event appears to be 3p loss and then a somatic VHL mutation
[36••]. Intriguingly, it has been suggested that because of the
long latency between 3p loss and clinical cRCC, it might be
possible to prevent the later development of cRCC by thera-
peutic targeting of cells harbouring a 3p deletion [36••].
pVHL Function and Oncogenic Drivers
of Tumourigenesis
Following the identification of the VHL TSG in 1993, there
were no clues to likely pVHL function from the primary pro-
tein sequence but, after reports that pVHL-deficient cRCC
cells showed abnormal levels of hypoxia-responsive
mRNAs (e.g. VEGF, PDGFB, GLUT1) in both normoxic
and hypoxic conditions, Maxwell et al. [37] demonstrated that
pVHL had a critical role in regulating the expression of the α-
subunits of the hypoxia-inducible transcription factors, HIF-1
and HIF-2 [1, 38]. Further studies have shown that pVHL
functions as the target binding component of an E3 ubiquitin
ligase complex that also contains elongin C, elongin B, cullin
2 and RBX1 (VCB-CR complex) [39–43] (see Fig. 2). In
normoxic conditions, the β-domain of pVHL binds to the
oxygen-dependent degradation domains of HIF-1α and HIF-
2α resulting in polyubiquitination and proteasomal degrada-
tion of the HIF α-subunits [37–43]. The ability of pVHL to
bind to the HIF α-subunits is dependent on hydroxylation of
two conserved proline residues. Oxygen is an essential cofac-
tor for the proline hydroxylation enzymes (PHD1, PHD2,
PHD3) and under hypoxic conditions, the HIF-α subunit pro-
line residues are not hydroxylated, pVHL is therefore unable
to bind and HIF-1 and HIF-2 are stably expressed and hypoxic
gene response pathways (> 200 genes) are activated [44, 45].
Biallelic VHL inactivation in tumour cells mimics the effect of
hypoxia and the resulting transcriptional response is thought
to drive both angiogenesis and oncogenesis. HIF-1 and HIF-2
have overlapping but different transcriptional targets and there
is evidence that HIF-2 is the primary driver of oncogenesis
(some studies suggest that HIF-1 is antioncogenic) [46–48].
The complex genotype-phenotype correlations observed in
VHL disease might suggest multiple and tissue-specific
pVHL functions and many HIF-dependent and HIF-
independent functions have been described including regula-
tion of extracellular matrix assembly, microtubule stability,
primary cilium signalling, cell cycle progression, senescence
and apoptosis and cellular metabolism (see 1, 38, 49 and ref-
erence within). In addition to HIF-1 and HIF-2 and other com-
ponents of the VCBC-R complex, pVHL has been reported to
interact with TP53 and absence of pVHL is associated with
reduced levels of TP53 [49].
There has been considerable interest in identifying pro-
teins, in addition to HIF-1 and HIF-2, that the VCBC-R com-
plex might regulate. Recently, Zhang et al. [50•] undertook a
screen to identify candidate proline-hydroxylation-dependent
pVHL-binding partners. A candidate TSG, ZHX2 was identi-
fied from the screen and confirmed to be targeted for
p ro t ea soma l degrada t ion by pVHL in a p ro ly l
hydroxylation-dependent manner. Further experiments dem-
onstrated that expression of ZHX2 (Zinc fingers and homeo-
boxes 2) was upregulated in pVHL-deficient cRCC tumour
cells and was oncogenic suggesting that ZHX2 could provide
a novel target for the development of therapies for cRCC
[50•].
The structure of the VCB complex has been elucidated and
two coupled pVHL domains identified, an α-domain that in-
teracts with elongin C and a β-domain that functions as the
substrate docking site and binds to HIF-1a [41]. The prototyp-
ic VHL disease type 2A (p.Tyr98His) and type 2B
(p.Arg167Trp/p.Arg167GLn) mutations (see Table 2) disrupt
respectively the HIF-1α/β-domain and the elongin C/α-do-
main binding sites. In a recent study, Minervini et al. [51] used
computational modelling to propose that five different inter-
faces of pVHL can be delineated and, using published data
from 360 VHL mutations and 59 proposed pVHL interactors,
they attempted to correlate the phenotypic effects of VHL
missense variants with their effect on the various interactors.
These findings will provide a framework for functional studies
aimed at determining the molecular basis for the complex
genotype-phenotype correlations observed in VHL disease
and VHL-related polycythaemia disorders.
Despite the evidence for multiple roles of pVHL, regula-
tion of HIF-1 and HIF-2 remains the best characterised and
most strongly linked to tumourigenesis. Previously, it was
demonstrated that it was possible to overcome the growth
suppressor activity of pVHL in cRCC cells by transfecting a
modified HIF-2 protein that did not bind pVHL [52].
Furthermore, the clinical utility of tyrosine kinase inhibitors
which antagonise the downstream effects of activation of the
hypoxic gene response pathway in metastatic RCC is well
established (although progression-free survival is increased,
they are not curative [53] it could be postulated that more
upstream inhibition of the pathway might be more effective.
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Whilst it was initially thought that the HIF transcription fac-
tors were undruggable, using knowledge of the HIF-2 struc-
ture, small molecule selective HIF-2 antagonists, PT2399 and
PT2385, were developed which suppressed the binding of
HIF-2a to its dimerization partner ARNT/HIF-1B [54, 55••,
56••]. The inhibitors were demonstrated to suppress the
growth of VHL-deficient cRCC cells in in vitro and in vivo
models though some VHL-mutant tumours were resistant to
treatment and prolonged treatment could lead to resistance
through the acquisition of mutations in HIF-2a and HIF-1B
[55••, 56••]. Subsequently, a phase 1 first-in-human study of
PT2385 was reported in patients with previously treated ad-
vanced or metastatic RCC and found to be well tolerated
(anaemia was the most common side effect). In 50 patients,
complete response, partial response, stable disease and tumour
progression were observed in 2%, 12%, 52% and 34% respec-
tively [57•].
Management of VHL Disease
Tumour Surveillance Protocols
Large clinical studies demonstrating that the lifetime risks of
retinal and cerebellar haemangioblastomas and cRCC in indi-
viduals with VHL disease exceeded 70% led to the recom-
mendation that affected individuals and their at risk relatives
should be offered annual screening from childhood [4, 6].
Whilst screening protocols may differ between centres and
countries, there is clear evidence that surveillance reduces
morbidity and mortality in individuals with VHL disease
[58]. A recent UK national audit of centres treating patients
with VHL disease (Sandford unpublished observations)
showed complete compliance with a previously published
screening protocol [6] though there was some variation in
whether ultrasonogrophy (USS) or MRI scans are used for
Fig. 2 The role of pVHL in oxygen-dependant hypoxia-inducible factor
regulated gene expression. Under conditions of normal cellular oxygen
levels, hypoxia-inducible factors α-subunits (HIF1α and HIF2α) are
hydroxylated by prolyl hydroxylases. Prolyl-hydroxylated HIFα is
recognised by the pVHL–elongin C (ELC)–elongin B–cullin 2
(CUL2)–RBX1 (VCB–CR) E3 ubiquitin ligase complex and targeted
for ubiquitylation (Ub) and proteasomal degradation. In hypoxic
conditions, prolyl hydroxylases are inactive and HIFα accumulates and
forms heterodimers with HIF1β which translocate to the nucleus, bind
hypoxia-response elements (HREs) and induce gene transcription. The
absence of VHL therefore leads to the constitutive activation of these
hypoxic responsive genes (adapted from Gossage et al. (1))
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annual abdominal screening. Our own policy is to use annual
Magnetic Resonance Imaging (MRI) screening but at a recent
UK Cancer Genetics Group meeting the consensus was to
start annual abdominal screening between 14 and 16 years
by USS, and from age 16 years, alternate annually between
MRI and USS (see CGG Spring Meeting Workshop 2019 at
https://www.ukcgg.org/information-education/ukcgg-
consensus-meetings/). A notable transformation in the
management of VHL disease in the last three decades has
been in relation to the early detection and treatment of
r e t i na l haemang iob la s tomas and RCC. Annua l
ophthalmological surveillance and early treatment of small
retinal haemangioblastomas has been adopted worldwide
(though optic nerve haemangioblastomas may present
difficult treatment decisions) [59]. Similarly, annual renal
imaging has enabled early detection of tumours and there
has been worldwide acceptance of the “3-cm rule”. Small
asymptomatic solid renal lesions are followed until they
reach 3-cm diameter and are then treated using a nephron-
sparing approach such as partial nephrectomy, radiofrequency
or cryo-ablation [60, 61]. The high incidence of multicentric
RCC in VHL disease means that patients may require multiple
interventions but a “nephron-sparing strategy” has reduced the
need for renal replacement therapy in patients with bilateral
synchronous or metachronous RCC [60–62].
Although the need for annual surveillance programmes
for patients with VHL disease is universally agreed and
adopted, there is some variability in the fine details of
surveillance programmes (e.g. age at which surveillance
should commence, frequency of screening for CNS
haemangioblastomas and screening for rare manifesta-
tions) and what follow-up should be offered to individuals
with an apparently sporadic CNS haemangioblastoma and
no detectable VHL mutation. It is likely that many, espe-
cially older, cases of CNS haemangioblastoma are not rou-
tinely offered VHL gene testing at all. These differences
can reflect how low levels of risk are perceived (e.g. should
screening start dates be based on exceptional early onset
cases or a specific risk threshold—and if so, should this be
1%, 2% etc.) and, for rarer manifestations, limited data on
which to base a decision. Within UK centres, there is var-
iability in screening for pancNETs and ELSTs. Pancreatic
tumours occur in ~ 10–15% of patients and previously, it
has been suggested that pancNETs in VHL disease should
be removed when they reached a diameter of 2–3 cm [63].
However, it is important to avoid overtreatment and to
distinguish between cystadenomas (which do not require
removal) and pancNETs. In a recent multicentre interna-
tional study of 485 pancNETs that occurred in 273 of 2330
(11.7%) patients with VHL disease, 20% had metastatic
disease [64]. Predictors of metastatic disease were a tu-
mour diameter > 2.8 cm, high tumour growth rate and
germline missense mutations at codon 167 and so the
management of pancreatic lesions might be personalised
according to patient-specific characteristics [64, 65].
Though the frequency of ELST in VHL disease has been
reported to be as high as 11–16% in cohorts in which ELST
has been screened for [66], a recent study reported a much
lower frequency of 3.6%, with ELST being the initial mani-
festation of VHL in 32% of these cases [67]. This latter figure
is more consistent with the frequency in UK centres (Sandford
et al. unpublished).
A concern for many women with VHL disease is whether
pregnancy might lead to a hastening of tumour growth. In our
experience, this has not occurred but in the literature, there are
case reports of women presenting during pregnancy with a
symptomatic haemangioblastoma. A recent report from
Denmark provides some reassurance regarding pregnancy-
related risks as no evidence was found that pregnancy aggra-
vated the development of VHL tumours [68]. Though this was
a small study (17 women completed 30 pregnancies), it is in
accordance with our own practice in which we organise base-
line scans in women who are planning to become pregnant
and do not perform more frequent surveillance during preg-
nancy if there is no evidence of tumours.
Therapeutic Options in VHL Disease
In cases of VHL disease undergoing annual surveillance, the
early detection and treatment pathways for symptomatic reti-
nal haemangioblastomas and cRCC are well established (see
above). For central nervous system haemangioblastomas, the
detection of an asymptomatic lesion will usually not result in
surgical removal as the risks of intervention and neurological
deficit need to be balanced against the possibility that the
haemangioblastomas may remain asymptomatic and static or
slow growing. Hence, regular monitoring will usually be ini-
tiated and surgery delayed until symptoms develop
(haemangioblastomas associated with a cyst are more likely
to become symptomatic). Radiosurgery has been used with
some success in some centres as an alternative to neurosurgi-
cal removal [69] but the management of patients with multiple
or recurrent haemangioblastomas, particularly in the spinal
cord or brain stem, can be extremely challenging and the
availability of effective medical approaches would be a major
advance. Though there have been suggestions that the widely-
used beta-blocker propranolol [70, 71] or the somatostatin
analogue ocreotide [72] might provide a potential therapeutic
option, there are no reports from prospective well-powered
clinical trials. Tyrosine kinase inhibitors such as sorafenib,
sunitnib and pazopanib have been show to extend
progression-free survival in metastatic cRCC (see above)
and seemingly should provide an option for systemic treat-
ment in patients with VHL disease. In a prospective phase 2
clinical trial of pazopanib, Jonasch et al. [73•] treated 31 pa-
tients with pazopanib and observed a partial response in 42%
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of cases with the remaining having stable disease as the best
response. The results varied by tumour site with 52% of RCC
(n = 59, median shrinkage = 40.5%) and 53% of pancreatic
lesions (predominantly serous cystadenomas) (responding
but only 4% of CNS haemangioblastomas (n = 49, median
shrinkage = 13%)). It is not clear whether long-term
pazopanib treatment would alter the growth trajectory of
CNS lesions and pazopanib treatment is associated with sig-
nificant side effects that may require cessation of treatment.
Nevertheless, this single-arm trial does suggest that systemic
therapy with pazopanib might be an option for patients in
whom more conventional therapies are not available or con-
traindicated. Furthermore, the work of Jonasch et al. [73•] will
encourage further efforts to develop systemic treatments with
improved efficacy and less toxicity. Small molecule HIF-2
antagonists are attracting great interest and an international
trial is ongoing to investigate whether oral administration of
PT2977 (a small molecule that is similar but more active than
PT2385) to patients with small cRCC (< 3 cm) is associated
with RCC and non-RCC tumour stabilisation or shrinkage
(https://clinicaltrials.gov/ct2/show/NCT03401788).
Conclusions
Substantial progress has been made in our knowledge of the
clinical and molecular features of VHL disease in the past
30 years [1, 2, 4] and the implementation of early genetic
diagnosis, tumour surveillance programmes and agreed treat-
ment approaches (e.g. 3-cm rule for renal lesions) has reduced
morbidity and mortality [58]. Major challenges remain, and
the development of non-toxic systemic therapies for VHL is a
major goal yet to be achieved. However, there has been some
progress towards this aim and the fundamental role that the
VHLTSG plays in sporadic cRCCmeans that individuals with
VHL disease should benefit from research and drug develop-
ment that is primarily aimed at a much more common disor-
der. Another major aimmust be to ensure that every individual
with a pathogenic VHL variant is diagnosed early so that a
surveillance programme can be initiated and their at-risk rela-
tives identified and offered testing and surveillance. The mo-
lecular genetic tools for achieving this are available but in our
experience, not all individuals who might benefit from genetic
testing (e.g. patients with haemangioblastomas, PPGL etc.)
are offered molecular analysis and this can result in later di-
agnosis in some cases. It is hoped that the mainstreaming of
genomics testing in countries such as the UK and the interna-
tional initiatives such as ClinGen [74] will improve both ac-
cess to and the accuracy of genetic testing and further reduce
avoidable morbidity and mortality from VHL disease.
Acknowledgements We apologise to all the authors whose papers we
were unable to cite because of space constraints.
Funding Information We thank the European Research Council
(Advanced Researcher Award (EM)), NIHR (Senior Investigator Award
(EM) and Cambridge NIHR Biomedical Research Centre (EM, RS)) and
Cancer Research UK Cambridge Cancer Centre (EM) for research sup-
port. The University of Cambridge has received salary support in respect
of EM and RS from the NHS in the East of England through the Clinical
Academic Reserve.
Compliance with Ethical Standards
Conflict of Interest Dr. Maher declares personal fees as a consultant to
Illumina, and his role as a medical advisor toVHL Patient support groups.
Dr. Sandford declares no conflict of interest.
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of
the authors.
Disclaimer The views expressed are those of the authors and not neces-
sarily those of the NHS or Department of Health.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour sup-
pressor gene. NatRev Cancer. 2015;15(1):55–64.
2. Nielsen SM, Rhodes L, Blanco I, Chung WK, Eng C, Maher ER,
et al. Von Hippel-Lindau disease: genetics and role of genetic
counseling in a multiple neoplasia syndrome. J Clin Oncol.
2016;34(18):2172–81.
3. Richards FM, Payne SJ, Zbar B, Affara NA, Ferguson-Smith MA,
Maher ER.Molecular analysis of de novo germlinemutations in the
von Hippel-Lindau disease gene. Hum Mol Genet. 1995;4(11):
2139–4.
4. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT,
et al. Clinical features and natural history of von Hippel-Lindau
disease. Q J Med. 1990;77(283):1151–63.
5. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher
ER. Genotype-phenotype correlations in von Hippel-Lindau dis-
ease. Hum Mutat. 2007;28:143–9.
6. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a
clinical and scientific review. Eur J Hum Genet. 2011;19(6):617–
23.
7. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-
Lindau disease tumor suppressor gene. Science (New York, N.Y.).
1993;260(5112):1317–20.
Curr Genet Med Rep (2019) 7:227–235 233
8. Tabaro F, Minervini G, Sundus F, Quaglia F, Leonardi E, Piovesan
D, et al. VHLdb: a database of von Hippel-Lindau protein
interactors and mutations. Sci Rep. 2016;6:31128.
9. Ang SO, Chen H, Gordeuk VR, Sergueeva AI, Polyakova LA,
Miasnikova GY, et al. Endemic polycythemia in Russia: mutation
in the VHL gene. Blood Cells Mol Dis. 2002;28(1):57–62.
10. Coppin L, Grutzmacher C, Crépin M, Destailleur E, Giraud S,
Cardot-Bauters C, et al. VHLmosaicism can be detected by clinical
next-generation sequencing and is not restricted to patients with a
mild phenotype. Eur J Hum Genet. 2014;22(9):1149–52.
11. Coppin L, Plouvier P, CrépinM, Jourdain AS, Ait Yahya E, Richard S,
et al. Optimization of next-generation sequencing technologies for von
Hippel Lindau (VHL) mosaic mutation detection and development of
confirmation methods. J Mol Diagn. 2019;21:462–70.
12. Albanyan S, Giles RH, Gimeno EM, Silver J, Murphy J, Faghfoury
H, et al. Characterization of VHL promoter variants in patients
suspected of Von Hippel-Lindau disease. Eur J Med Genet.
2019;62:177–81.
13.• Lenglet M, Robriquet F, Schwarz K, Camps C, Couturier A,
Hoogewijs D, et al. Identification of a new VHL exon and complex
splicing alterations in familial erythrocytosis or von Hippel-Lindau
disease. Blood. 2018;132(5):469–83. Identification of intronic
mutations in individuuals without previously detected patho-
genic variants.
14. Flores SK, Cheng Z, Jasper AM, Natori K, Okamoto T, Tanabe A,
et al. A synonymous VHL variant in exon 2 confers susceptibility to
familial pheochromocytoma and von Hippel-Lindau disease. J Clin
Endocrinol Metab. 2019. https://doi.org/10.1210/jc.2019-00235.
15. Maher ER, Yates JR, Ferguson-Smith MA. Statistical analysis of
the two stage mutation model in von Hippel-Lindau disease, and in
sporadic cerebellar haemangioblastoma and renal cell carcinoma. J
Med Genet. 1990;27(5):311–4.
16. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al.
Mutations of the VHL tumour suppressor gene in renal carcinoma.
Nat Genet. 1994;7(1):85–90.
17. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM,
Crossey PA, et al. Somatic mutations of the von Hippel-Lindau
disease tumour suppressor gene in non-familial clear cell renal car-
cinoma. Hum Mol Genet. 1994;3(12):2169–73.
18. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P,
et al. Analysis of VHL gene alterations and their relationship to
clinical parameters in sporadic conventional renal cell carcinoma.
Clin Cancer Res. 2009;15(24):7582–92.
19. Prowse AH, Webster AR, Richards FM, et al. Somatic inactivation
of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum
Genet. 1997;60(4):765–71.
20. Vortmeyer AO, Gnarra JR, Emmert-BuckMR, Katz D, LinehanWM,
Oldfield EH, et al. von Hippel-Lindau gene deletion detected in the
stromal cell component of a cerebellar hemangioblastoma associated
with von Hippel-Lindau disease. Hum Pathol. 1997;28(5):540–3.
21. Shankar GM, Taylor-Weiner A, Lelic N, Jones RT, Kim JC, Francis
JM, et al. Sporadic hemangioblastomas are characterized by cryptic
VHL inactivation. Acta Neuropathol Commun. 2014;2:167.
22. Webster AR, Richards FM, MacRonald FE, Moore AT, Maher ER.
An analysis of phenotypic variation in the familial cancer syndrome
von Hippel-Lindau disease: evidence for modifier effects. Am J
Hum Genet. 1998;63(4):1025–35.
23. Fei SS, Mitchell AD, Heskett MB, Vocke CD, Ricketts CJ, Peto M,
et al. Patient-specific factors influence somatic variation patterns in von
Hippel-Lindau disease renal tumours. Nat Commun. 2016;7:11588.
24. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci
on the short arm of chromosome 3 in renal cell carcinoma. Nature.
1987;327(6124):721–4.
25. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER.
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene
and allelic losses at chromosome arm 3p in primary renal cell
carcinoma: evidence for a VHL-independent pathway in clear cell
renal tumourigenesis. Genes Chromosom Cancer. 1998;22(3):200–9.
26. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires
MM, et al. Patterns of gene expression and copy-number alterations
in von-Hippel Lindau disease-associated and sporadic clear cell
carcinoma of the kidney. Cancer Res. 2009;69(11):4674–81.
27. Cancer Genome Atlas Research Network. Comprehensive molec-
ular characterization of clear cell renal cell carcinoma. Nature.
2013;499(7456):43–9.
28. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A,
et al. Systematic sequencing of renal carcinoma reveals inactivation
of histone modifying genes. Nature. 2010;463(7279):360–3.
29. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al.
Exome sequencing identifies frequent mutation of the SWI/SNF
complex gene PBRM1 in rena l ca rc inoma. Nature .
2011;469(7331):539–42.
30. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-
Jiménez A, Wang S, et al. BAP1 loss defines a new class of renal
cell carcinoma. Nat Genet. 2012;44(7):751–9.
31.•• Ricketts CJ, DeCubasAA, FanH, Smith CC, LangM, Reznik E, et al.
CancerGenomeAtlas ResearchNetwork, SpellmanPT,RathmellWK,
LinehanWM.The cancer genome atlas comprehensivemolecular char-
acterization of renal cell carcinoma. Cell Rep. 2018;23(12):3698.
Large-scale renal cell carcinoma cancer genomic study.
32. Wang SS, GuYF,Wolff N, Stefanius K, Christie A, Dey A, et al. Bap1
is essential for kidney function and cooperates with Vhl in renal tumor-
igenesis. Proc Natl Acad Sci U S A. 2014;111(46):16538–43.
33. Gao W, Li W, Xiao T, Liu XS, Kaelin WG Jr. Inactivation of the
PBRM1 tumor suppressor gene amplifies the HIF-response in
VHL-/- clear cell renal carcinoma. Proc Natl Acad Sci U S A.
2017;114(5):1027–32.
34. Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie
Y, et al. The SWI/SNF protein PBRM1 restrains VHL-loss-driven clear
cell renal cell carcinoma. Cell Rep. 2017;18(12):2893–906.
35. Espana-Agusti J, Warren A, Chew SK, Adams DJ, Matakidou A.
Loss of PBRM1 rescues VHL dependent replication stress to pro-
mote renal carcinogenesis. Nat Commun. 2017;8(1):2026.
36.•• Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O’Brien
T, et al. Timing the landmark events in the evolution of clear cell
renal cell cancer: TRACERx Renal. Cell. 2018;173(3):611–
623.e17. This study provides novel insights into the evolution
of clear cell renal cell carcinoma.
37. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC,
Cockman ME, et al. The tumour suppressor protein VHL targets
hypoxia-inducible factors for oxygen-dependent proteolysis.
Nature. 1999;399:271–5. https://doi.org/10.1038/20459.
38. Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P,
et al. Hypoxia, hypoxia-inducible transcription factors, and renal
cancer. Eur Urol. 2016;69(4):646–57.
39. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the
von Hippel-Lindau tumor suppressor protein to Elongin B and C.
Science. 1995;269:1444–6.
40. Kamura T, et al. Rbx1, a component of the VHL tumor suppressor
complex and SCF ubiquitin ligase. Pause, A. et al. The von Hippel-
Lindau tumor-suppressor gene product forms a stable complex with
human CUL-2, a member of the Cdc53 family of proteins. Proc
Natl Acad Sci U S A. 1997;94:2156–61.
41. Stebbins CE, Kaelin WG Jr, Pavletich NP. Structure of the VHL-
ElonginC-ElonginB complex: implications for VHL tumor sup-
pressor function. Science. 1999;284:455–61.
42. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC,
Conaway JW, et al. Identification of the von Hippel-Lindau tu-
mor-suppressor protein as part of an active E3 ubiquitin ligase
complex. Proc Natl Acad Sci U S A. 1999;96:12436–41.
Curr Genet Med Rep (2019) 7:227–235234
43. Cockman ME, et al. Hypoxia inducible factor-alpha binding and
ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
J Biol Chem. 275:25733–41.
44. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al.
HIFalpha targeted for VHL-mediated destruction by proline hy-
droxylation: implications for O2 sensing. Science. 2001;292:464–
8.
45. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ,
et al. Targeting of HIF-alpha to the von Hippel-Lindau
ubiquitylation complex by O2-regulated prolyl hydroxylation.
Science. 2001;292:468–72.
46. Hu CJ, Wang LY, Chodosh LA, et al. Differential roles of hypoxia-
inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic
gene regulation. Mol Cell Biol. 2003;23:9361–74.
47. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL,
et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1)
and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.
Mol Cell Biol. 2005;25:5675–86.
48. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M,
Signoretti S, et al. Genetic and functional studies implicate
HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov.
2011;1(3):222–35.
49. Roe JS, Youn HD. The positive regulation of p53 by the tumor
suppressor VHL. Cell Cycle. 2006;5(18):2054–6.
50.• Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, et al. VHL
substrate transcription factor ZHX2 as an oncogenic driver in clear
cell renal cell carcinoma. Science. 2018;361(6399):290–5. https://
doi.org/10.1126/science.aap8411. Identification of novel pVHL
target.
51. Minervini G, Quaglia F, Tabaro F, Tosatto SCE. Genotype-
phenotype relations of the von Hippel-Lindau tumor suppressor
inferred from a large-scale analysis of disease mutations and
interactors. PLoS Comput Biol. 2019;15(4):e1006478.
52. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr.
Inhibition of HIF is necessary for tumor suppression by the von
Hippel-Lindau protein. Cancer Cell. 2002;1(3):237–46.
53. Gul A, Rini BI. Adjuvant therapy in renal cell carcinoma. Cancer.
2019. https://doi.org/10.1002/cncr.32144.
54. Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, et al. A
small-molecule antagonist of HIF2α is efficacious in preclinical
models of renal cell carcinoma. CancerRes. 2016;76(18):5491–
500.
55.•• Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez
A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist.
Nature. 2016;539(7627):112–7.
56.•• Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, et al.
On-target efficacy of a HIF-2α antagonist in preclinical kidney
cancer models. Nature. 2016;539(7627):107–11.
57.• Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas
J, et al. Phase I dose-escalation trial of PT2385, a first-in-class
hypoxia-inducible factor-2α antagonist in patients with previously
treated advanced clear cell renal cell carcinoma. J Clin Oncol.
2018;36(9):867–87. References 55–58 describe the discovery
and potential use small molecule HIF-2 antagonist.
58. Maddock IR, Moran A, Maher ER, Teare MD, Norman A, Payne
SJ, et al. A genetic register for von Hippel-Lindau disease. J Med
Genet. 1996;33(2):120–7.
59. Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J,
et al. Management of retinal hemangioblastoma in von Hippel-
Lindau disease. Retina. 2019. https://doi.org/10.1097/IAE.
0000000000002572.
60. Steinbach F, Novick AC, Zincke H, Miller DP, Williams RD, Lund
G, et al. Treatment of renal-cell carcinoma in von Hippel-Lindau
disease - a multicenter study. J Urol. 1995;153:1812–6.
61. Walther MM, Choyke PL, Glenn G, Lyne JC, Rayford W, Venzon
D, et al. Renal cancer in families with hereditary renal cancer: pro-
spective analysis of a tumor size threshold for renal parenchymal
sparing surgery. J Urol. 1999;161:1475–9.
62. Goldfarb DA, Neumann HPH, Penn I, et al. Results of renal trans-
plantation in patients with renal cell carcinoma in Von Hippel-
Lindau disease. Transplantation. 1998;64:1726–9.
63. Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M,
Lubensky I, et al. Pancreatic neuroendocrine tumors associated
with von Hippel Lindau disease: diagnostic and management rec-
ommendations. Surgery. 1998;124(6):1153–9.
64. Krauss T, Ferrara AM, Links TP,Wellner U, Bancos I, Kvachenyuk
A, et al. Preventive medicine of von Hippel-Lindau disease-associ-
ated pancreatic neuroendocrine tumors. Endocr Relat Cancer.
2018;25(9):783–93.
65. Tirosh A, Sadowski SM, LinehanWM, Libutti SK, Patel D, Nilubol
N, et al. Association of VHL genotype with pancreatic neuroendo-
crine tumor phenotype in patients with von Hippel-Lindau disease.
JAMA Oncol. 2018;4(1):124–6.
66. Manski TJ, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz
D, Lebovics R, Sledjeski K, Choyke PL, Zbar B, Linehan WM,
Oldfield EH, Oldfield EH. Endolymphatic sac tumors. A source of
morbid hearing loss in von Hippel-Lindau disease. JAMA.
1997;277(18):1461–1466.
67. Bausch B, Wellner U, Peyre M, Boedeker CC, Hes FJ, Anglani M,
et al. International Endolymphatic Sac Tumor (ELST) Consortium.
Characterization of endolymphatic sac tumors and von Hippel-
Lindau disease in the International Endolymphatic Sac Tumor
Registry. Head Neck. 2016;38(Suppl 1):E673–9.
68. Binderup ML, Budtz-Jørgensen E, Bisgaard ML. New von Hippel-
Lindau manifestations develop at the same or decreased rates in
pregnancy. Neurology. 2015;85(17):1500–3.
69. Liebenow B, Tatter A, Dezarn WA, Isom S, Chan MD, Tatter SB.
Gamma knife stereotactic radiosurgery favorably changes the clin-
ical course of hemangioblastoma growth in von Hippel-Lindau and
sporadic patients. J Neuro-Oncol. 2019;142(3):471–8.
70. Albiñana V, Villar Gómez de Las HK, Serrano-Heras G, Segura T,
Perona-Moratalla AB, Mota-Pérez M, et al. Propranolol reduces
viability and induces apoptosis in hemangioblastoma cells from
von Hippel-Lindau patients. Orphanet J Rare Dis. 2015;10:118.
71. Shepard MJ, Bugarini A, Edwards NA, Lu J, Zhang Q, Wu T, et al.
Repurposing propranolol as an antitumor agent in von Hippel-
Lindau disease. J Neurosurg. 2018;1:1–9.
72. Sizdahkhani S, FeldmanMJ, PiazzaMG, KsendzovskyA, Edwards
NA, Ray-Chaudhury A, et al. Somatostatin receptor expression on
von Hippel-Lindau-associated hemangioblastomas offers novel
therapeutic target. Sci Rep. 2017;7:40822.
73.• Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu
D, et al. Pazopanib in patients with von Hippel-Lindau disease: a
single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018;19(10):
1351–9. Clinical trial for tyrosine kinase inhibitor in patients
with von Hippel-Lindau disease.
74. Rivera-Muñoz EA, Milko LV, Harrison SM, Azzariti DR, Kurtz
CL, Lee K, Mester JL, Weaver MA, Currey E, Craigen W, Eng C,
Funke B, Hegde M, Hershberger RE, Mao R, Steiner RD, Vincent
LM, Martin CL, Plon SE, Ramos E, Rehm HL, Watson M, Berg JS
ClinGen Variant Curation Expert Panel experiences and standard-
ized processes for disease and gene-level specification of the
ACMG/AMP guidelines for sequence variant interpretation. Hum
Mutat 2018 Nov;39(11):1614–1622.
Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Curr Genet Med Rep (2019) 7:227–235 235
